Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes - Wikidata - awgldk - TriplyDB

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

http://www.wikidata.org/entity/Q28262769

about

Mechanisms of action of glucagon-like peptide 1 in the pancreas The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis The pharmacological landscape and therapeutic potential of serine hydrolases Lixisenatide as add-on therapy to basal insulin Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation Design and synthesis of 4-(2,4,5-trifluorophenyl)butane-1,3-diamines as dipeptidyl peptidase IV inhibitors Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts Stereoselective synthesis of novel adamantane derivatives with high potency against rimantadine-resistant influenza A virus strains.Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors.Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.Screening of a natural compound library identifies emodin, a natural compound from Rheum palmatum Linn that inhibits DPP4.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Analysis of the proteolysis of bioactive peptides using a peptidomics approach.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial Saxagliptin for type 2 diabetes Antimicrobial and hypoglycemic activities of novel N-Mannich bases derived from 5-(1-adamantyl)-4-substituted-1,2,4-triazoline-3-thiones Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.The metabolic serine hydrolases and their functions in mammalian physiology and disease.Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation Investigating endogenous peptides and peptidases using peptidomics Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.Management of Type 2 diabetes: the role of incretin mimetics.Unstabilized azomethine ylides for the stereoselective synthesis of substituted piperidines, tropanes, and azabicyclo[3.1.0] systems Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.Exploration of the DPP-4 inhibitors with a focus on saxagliptin.Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.Incretin agents in type 2 diabetes.Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

P2860

Q24683764-77FB0BD8-0064-4263-917D-21B501AE7218 Q26795473-6B7D746E-D4F1-4F61-B167-2331D7136C58 Q26995817-3103F040-EC05-4380-97FA-1F459C3D2FA3 Q27007547-48911E3B-D566-4A61-A5DD-7D0F7133D35C Q27649728-A9C3CE36-6FD1-484E-8F06-6F2F99519E7F Q27684616-658E2524-41B4-4BD9-9DDC-F1889D04EA0D Q28483936-BD625EB1-1D4B-489C-A83D-1B947AFDBB1B Q30400276-3497023A-D2D0-4653-8EB2-DA1055B59C04 Q31036099-65453622-E935-420B-9D08-FFC0807420D3 Q33237060-7505E4B1-E7F1-44F1-B869-FADAFD497D39 Q33671491-6EA3175B-6DF3-46EE-B3AD-0FFCD88C2BA5 Q34219918-54C9A037-3CD3-45BF-963D-74D642507B66 Q34222114-63210115-E8DC-4A36-A281-333DD0247574 Q34329204-4BA2B6DE-1F10-41EC-91B5-8054D4EACCDD Q34573849-BF05EA88-7DEA-415C-AD78-2B1E45DFB00F Q34608300-F857C477-55E0-43C5-8520-702C831FCA28 Q34610019-345743F1-EB4D-4D8F-B307-C6C1A7A3CFFD Q34620486-4E4DEBBF-124C-49E6-89CA-C8057D4DDF75 Q34835155-A2F74E1C-91E9-4221-9C3B-F862D72F04A7 Q35115112-9B55E896-B3A7-4DDD-BA1A-90DDAD1270A6 Q35131941-59E78235-4B27-4411-B06B-F2DBEA0BAA12 Q35333042-C11A23F0-EBAF-4C83-BA4C-E5AC45268951 Q35916947-8106B24C-A3FA-4CC5-8EBF-5EB78056138E Q36163374-0018C787-4164-4442-8B32-F641DA29F17D Q36355550-4129DEF3-F922-4DAF-98AB-E628FC5292A1 Q36470223-B52FD951-27A8-4E00-9A3A-CF148387A3A7 Q36580568-7FCFD451-65E5-4490-800D-C9179963B9D5 Q36580608-7CC80CEC-3D5F-40CF-A056-94FE97B107A5 Q36613938-4DE28175-B709-4137-88DE-7C924C894012 Q36651992-DEE0CAF7-3F62-44B5-BD9D-04680006C0A0 Q36735761-3CC87722-3124-4D89-85B2-7871E6A2B0BE Q36892807-E80B5140-F79C-446D-A733-3CF6901DC8F8 Q36939647-9B2A1222-D4D2-4157-BAF1-1040D796AB9F Q37358680-6E0EEEEC-CF1B-41E9-9F0C-1026EE0CD517 Q37384190-AAF27ED8-BA3E-4A1D-BAD8-0E37763E8F95 Q37603371-28CEEA78-3C13-46E2-8D35-FD81B4373F62 Q37636165-5A319844-C4B6-4954-AFF2-CCDE0F960D9F Q37682555-77368689-2E5C-4A7D-B82B-1418772DE283 Q37772709-538E0E3C-5BFB-47D7-B3E6-0EA6412389A7 Q37941683-D33B5B92-12EC-4913-90B5-B9531CBE8D8E

P2860

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

http://www.wikidata.org/entity/Q28262769

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@ast

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@en

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@nl

type

label

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@ast

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@en

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@nl

prefLabel

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@ast

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@en

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@nl

P1433

Q28262769-9BF401D7-27B2-4C8F-98B5-1DFBA88FF271

P1476

Q28262769-C67C33D9-0CD6-4ADE-A40D-B50F4B9DEE4E

P2093

Q28262769-0AEADDA3-3768-4C10-BC54-E978FA7595C0

Q28262769-116D75C0-D4CB-4531-9471-C854407A6425

Q28262769-21AC5B6E-EE4F-4350-9C5F-530B9D51E516

Q28262769-281D80A2-4AD1-4AA3-B0B8-E58798F313CB

Q28262769-29243A0B-8C27-49F3-A815-5349177D625D

Q28262769-38EA467D-6F51-4557-BB5A-5AE4F9C5738C

Q28262769-391F45A0-6026-401E-993B-A167D775A083

Q28262769-4455468B-2064-4B3B-A53D-C5B29AA302D4

Q28262769-49A2B098-DC62-4745-8674-E4B8AA4D9E23

Q28262769-4BC793BC-2ADE-46F2-A909-8477D203D369

P304

Q28262769-D7B4107A-B6EB-40E1-82B8-B08D685C268A

P31

Q28262769-6C325653-9500-4B37-8BDB-2F62D102920C

P3181

Q28262769-F14A2CD0-0AA1-4405-B9A4-77A0A73ECE5E

P356

Q28262769-0114B021-BCF9-4FED-A8C5-D60F759659E6

P407

Q28262769-879EA80A-9BFC-4AF7-A9C4-B4E44F212D8C

P433

Q28262769-72C1027A-5F07-44FA-86DF-08E291EECB89

P478

Q28262769-69EE7D74-EE7B-4B64-854F-4659D1357932

P577

Q28262769-9D20E6E9-6B33-46F2-ABB3-1383B94D2AA4

P5875

Q28262769-8CBF6327-5253-4139-AE54-E717F832DDAF

P698

Q28262769-1A68E4CB-61AC-4C80-89F1-9C3A1057425B

P921

Q28262769-534FCF8B-EEAC-4204-9FAD-7C055A5B3E2C

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery and preclinical prof ...... e treatment of type 2 diabetes

@en

P2093

Aiying Wang

http://www.w3.org/2001/XMLSchema#string

Ashish Khanna

http://www.w3.org/2001/XMLSchema#string

Benoni Abboa-Offei

http://www.w3.org/2001/XMLSchema#string

David A Betebenner

http://www.w3.org/2001/XMLSchema#string

David J Augeri

http://www.w3.org/2001/XMLSchema#string

David R Magnin

http://www.w3.org/2001/XMLSchema#string

Donald M Egan

http://www.w3.org/2001/XMLSchema#string

Effie Tozzo

http://www.w3.org/2001/XMLSchema#string

Gustav E Welzel

http://www.w3.org/2001/XMLSchema#string

James G Robertson

http://www.w3.org/2001/XMLSchema#string

P304

5025-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3201596

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM050261P

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7712519

http://www.w3.org/2001/XMLSchema#string

P698

16033281

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes